Drug, bio-affecting and body treating compositions inventions 08/06

20060193768 - Contrast agent: A contrast agent of formula I: V-L-R (I) where V is an organic group having binding affinity for an angiotensin II receptor site, L is a linear or branched amino acid-comprising biomodifier or linker moiety, and R is a reporter moiety detectable in in vivo imaging of a human or...

20060193769 - Drug releasing biodegradable fiber for delivery of therapeutics: The present invention relates to fiber compositions comprising gels or hydrogels. The invention further relates to the composition of a gel or hydrogel loaded biodegradable fiber and methods of fabricating such fibers. The present invention further provides tissue engineering and drug-delivery compositions and methods wherein three-dimensional matrices for growing cells...

20060193771 - Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins: CD30 is a receptor expressed on cells of Hodgkin's disease and certain leukemias. The extracellular portion of CD30 is cleaved, releasing a form known as sCD30. The invention relates in part to the discovery that a residual, extracellular “stalk” of CD30 remains after cleavage of sCD30. The stalk provides an...

20060193772 - Drugs for treating cancer: The invention aims to provide a medicament for treating cancer in which a cancer therapeutic effect is synergistically increased using a substance inhibiting activities of insulin-like growth factor-I (IGF-I) and insulin-like growth factor-II (IGF-II). According to the invention, there are provided a medicament for treating cancer which comprises a substance...

20060193770 - Method of determining cytokine dosage for myelosuppressive state: The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By establishing threshold levels of certain cytokines as a surrogate for myelosuppression, treatment protocols can be optimized to reduce myelotoxicity, while maximizing effective...

20060193775 - Embedder compositions and methods for detecting and killing cells in acidic areas of tumors: Embedder compositions effective for detecting or killing cells in acidic areas of tumors are described. Each composition includes an embedder peptide which at pH 7.2 and above is poly-anionic and so repels from cells in normal tissues, but at lower pH in hypoxic areas of tumors the embedder peptide converts...

20060193773 - Imaging agents: The invention relates to compounds of formula (I): and their use as targeting vectors that bind to receptors associated with angiogenesis. Such compounds may thus be used for diagnosis or therapy of, for example, malignant diseases, heart diseases, endometriosis, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma....

20060193774 - Transporter compositions and methods for detecting and killing cells in acidic areas of tumors: Improved transporter compositions effective for detecting or killing cells in acidic areas of tumors are described. Each composition includes a transporter peptide which at pH 7.2 and above is poly-anionic and so repels from cells in normal tissues, but at lower pH in hypoxic areas of tumors the transporter peptide...

20060193777 - Method of screening compounds for potential efficacy for the treatment of signs of aging: The present invention features a method of screening a compound for potential efficacy for the treatment of at least one sign of aging on the skin selected from the group consisting of enhancing the elasticity of said skin, enhancing the firmness of said skin, or reducing the appearance of wrinkles...

20060193776 - Screening methods employing zebrafish and the blood brain barrier: Use of fish, in particular zebrafish, in screening for substances with an ophthalmological effect or biological effect on the brain or central nervous system and/or effect on a disease or disorder of the brain or central nervous system. Based on identification and characterisation of the blood brain barrier....

20060193781 - Magnetic resonance imaging of metal concentrations: Provided herein is a method of magnetic resonance imaging (MRI) for in vivo mapping of concentration of a target metal ion in at least one tissue using a contrast agent selectively sensitive for the amount of target metal ion where the contrast agent itself contains a non-hydrogen imaging nucleus. Also...

20060193779 - Dental compositions having anti-stokes up converters and methods of use: A dental composition can include at least one polymerizable resin and at least one anti-stokes up converter. Alternatively, a two-part composition can include at least one dental composition configured for placement onto a person's tooth, and at least one anti-stokes up converter to be combined with the at least one...

20060193780 - Fluorescent membrane intercalating probes: The invention relates to a family of cyanine dyes which fluoresce in the far red and near infra red wavelengths of the spectrum and preferably prossess lipophilic side chains. The dyes of the invention are soluble in commercially available membrane staining vehicles, are useful as probes for rapidly staining lipophilic...

20060193778 - Receptor-mediated uptake of peptides that bind the human transferrin receptor: Peptides have been discovered which are capable of binding to and internalizing with the human transferrin receptor (hTfR). The sequences HAIYPRH (Seq. ID No. 1) and THRPPMWSPVWP (Seq. ID No. 2) are capable of binding to and internalizing with the human transferrin receptor. When these molecules were fused with other...

20060193782 - Abuse-proofed dosage form: The invention relates to a form of administration which is secured against misuse and which is thermoformed without extrusion, including at least one synthetic or natural polymer having a resistance to breaking of at least 500 N in addition to one or several active ingredients with a misuse potential and,...

20060193783 - Low dose corticosteroid composition: The present invention relates to a low dose composition of budesonide suitable for administration of budesonide to mucosal membranes for the management of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent...

20060193785 - Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent: Aerosol solution formulation for use in an aerosol inhaler which includes at least one active ingredient selected from 20-ketosteroids and quinolinone derivatives, a propellant containing a hydrofluoroalkane, a cosolvent, and a specific amount of a sequestering agent that stabilizes the formulation. By way of example, the stabilizing agent may be...

20060193786 - Pharmaceutical composition for intranasal administration containing a cgrp antagonist: The invention relates to pharmaceutical compositions for nasal application, comprising selected CGRP antagonists which are described in WO 98/11128, as well as a process for the preparation thereof....

20060193784 - Scopolamine sublingual spray for the treatment of motion sickness: This invention relates to a scopolamine spray for sublingual administration, used in the treatment and prevention of motion sickness, as well as the treatment and prevention of similar symptoms, such as nausea and vomiting, caused by conditions other than motion sickness. Also provided are methods of treatment, prevention and inhibition...

20060193788 - Acute treatment of headache with phenothiazine antipsychotics: Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic....

20060193787 - Nanoparticle-based drug delivery system: A drug delivery system based on at least one type of nanoparticle. In particular, a nanoparticle-based drug delivery system including at least one first drug, at least one second drug and at least one type of nanoparticle....

20060193789 - Film forming foamable composition: A foamable composition, includes (1) about 6% to about 70% by weight of at least one organic carrier; (2) about 0.1% to about 5% by weight of at least one surface-active agent; (3) about 0.01% to about 5% by weight of at least one film forming agent; (4) water; and...

20060193790 - Promoting whole body health: The present invention relates to promoting whole body health in humans and animals by using topical oral compositions comprising a safe and effective amount of a host-response modulating agent in admixture with a pharmaceutically acceptable carrier, said compositions being effective in mediating host reaction to the presence of periodontal pathogens...

20060193791 - Antiplaque oral care compositions: e

20060193792 - Use of an oral composition: Liquid dentifrice compositions are provided which give improved cleaning performance and flavour display when used in the small amounts that can be dispensed onto a typical electric toothbrush head. The liquid dentifrice has a viscosity of less than about 500 Pa·s at 0.1 s−1 at 25° C. Representative compositions include...

20060193793 - Apparatus and method for whitening teeth: Disclosed herein is a pair of dry type patches for teeth whitening, having a patch for upper teeth and a patch for lower teeth, in which the patch for upper teeth has a shape different from the patch for lower teeth, and each patch has a controlled width and shape...

20060193794 - Patches for teeth whitening: The present invention relates to a dry type tooth-whitening patch comprising peroxide as a tooth whitening agent. In particular, disclosed is a dry type tooth-whitening patch in which peroxide is contained, as a teeth whitening agent, in a matrix type adhesive layer. The adhesive layer includes, as a base polymer...

20060193795 - Appetite suppressant mouth spray: An appetite suppressant mouth spray formulation which simultaneously suppresses the user's appetite while promoting intraoral health. The mouth spray composition includes mouth spray base ingredients; and a plurality of appetite suppressant and appetite depressant herbs. The mouth spray base ingredients include a combination of Water; Glycerin; Xylitol; Propylene Glycol; Sodium...

20060193798 - Aqueous polymer dispersion: An aqueous polymer dispersion prepared by free-radical polymerization of vinyl acetate in the presence of at least one ionic emulsifier, at least one free-radical initiator and at least one protective colloid, wherein the polymerization is carried out in the presence of a polymerization regulator and wherein the ratio by weight...

20060193797 - Chroman derivatives as lipoxygenase inhibitors: wherein X and R1 to R10 are as described in the specification, and where either R5 is OH, —NRdORa or —NRd—NRbRc, or R7 is —NRdORa or —NRd—NRbRc, or C═R7R8 is C═NORa or C═N—NRbRc, which may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenases. They...

20060193796 - Method for refining ultraviolet absorbent, ultraviolet absorbent and cosmetic material: The process for purifying an ultraviolet absorber of the present invention is characterized by including an adsorbent treatment step of bringing the ultraviolet absorber into contact with an absorbent. According to the process, an ultraviolet absorber having a reduced odor, an improved hue and less skin irritation can be obtained....

20060193799 - Method of making perfluorocarbon emulsions with non-fluorinated surfactants: The present invention provides a method of making a FC emulsion. The method comprises mixing an FC immiscible hydrophilic liquid and a solid emulsifying agent by agitation at a temperature elevated above the phase transition temperature of the emulsifying agent and below the boiling temperature of the FC immiscible hydrophilic...

20060193801 - Solid cosmetic composition textured with an organic copolymer: The present invention relates to a solid cosmetic composition wherein it comprises a liquid fatty phase textured with an effective amount of at least one organic copolymer and in that it has a hardness ranging from 10 to 250 g and an elasticity of greater than 80%....

20060193800 - Variable tint cosmetics: The disclosed systems and methods for delivery of variable tint pigment materials in cosmetic concealer/foundation products generally include anhydrous carrier particles adapted to carry pigment. The pigmentation carrier particles may be optionally admixed with anhydrous (optionally tinted) base formulation material that is suitably adapted to suspend and/or separate the pigmentation...

20060193802 - Aldehyde and alcohol compositions derived from seed oils: An aldehyde composition derived by hydroformylation of a transesterified seed oil and containing a mixture of formyl-substituted fatty acids or fatty acid esters having the following composition by weight: greater than about 10 to less than about 95 percent monoformyl, greater than about 1 to less than about 65 percent...

20060193804 - Haircare use of cyclic amine derivatives: m represents an integer ranging from 0 to 5; and n represents an integer ranging from 0 to 5. or a salt or isomer thereof, leaving the said composition in contact with the keratin fibers and/or the skin from which the fibers emerge, and optionally rinsing the keratin fibers and/or...

20060193803 - Polymer particle dispersions, cosmetic compositions comprising at least one polymer particle dispersion, and cosmetic process using same: Disclosed herein is a dispersion of polymer particles in a liquid carbon-based medium, wherein said polymer is chosen from at least one block copolymer comprising at least one first block that is soluble in said liquid carbon-based medium and at least one second block that is insoluble in said liquid...

20060193805 - Method of preparing emulsions containing elastomeric silanes and siloxanes having quaternary ammonium groups: Oil-in-water (O/W) and water-in-oil (W/O) emulsions and microemulsions containing elastomeric silanes or siloxanes preferably having quaternary ammonium groups are generally made by reacting organic quaternary ammonium compounds having epoxide groups or halohydrin groups, with silanes or siloxanes having amino groups. The reaction is carried out in an aqueous polar phase...

20060193806 - Skin-pampering cream lotion: The cosmetic composition of the invention has a dynamic viscosity/shear stress flow curve with a maximum of up to 10000 Pa·s at the 5-50 Pa region and a shoulder at shear stress 30-110 Pa. The flow curve is determined at 25° C. on a Rheometric Scientific device having a parallel...

20060193817 - Hair or skin conditioning compositions comprising hydrophobically modified amido silicone copolyol: Disclosed are hair or skin conditioning compositions comprising by weight: (a) from about 0.1% to about 10% of a thickening polymer system; (b) from about 0.1% to about 8.0% of a surfactant system selected from the group consisting of cationic surfactant, nonionic surfactant, and mixtures thereof; (c) from about 0.1%...

20060193807 - Charging composition for coating keratin fibers comprising an aprotic wax: The present disclosure relates to a composition for coating keratin fibers, comprising, in a cosmetically acceptable continuous aqueous medium, at least one aprotic wax in an amount of greater than 25% by weight relative to the total weight of the composition, said composition having a dry extract of greater than...

20060193808 - Composition for coating keratin fibers, comprising a fatty alcohol wax and a cellulose-based polymer: The present disclosure relates to a composition for coating keratin fibers, comprising, in a cosmetically acceptable aqueous medium, at least one fatty alcohol wax, and at least one cellulose-based polymer. The present disclosure further relates to the use of such a composition to obtain charging makeup for keratin fibers....

20060193809 - Skin care compositions containing a sugar amine cross reference to related application: Topical skin care compositions containing sugar amines in combination with selected skin care actives and methods of using such compositions to regulate the condition of skin are disclosed. The compositions contain a safe and effective amount of a sugar amine in combination with either a safe and effective amount of...

20060193810 - Water-in-oil type micro-emulsion: A water-oil type micro-emulsion having high safety to a living body by decreasing the amount of a surfactant to be used or not using the surfactant, and at a high ratio of aqueous phase capable of dissolving effective ingredients, the water-in-oil type micro-emulsion comprising polyvinyl pyrrolidone and one or more...

20060193811 - Composition serving as a carrier for delivery of active ingredients in cosmetic and dermatological applications: The present invention is for a carrier comprising an oil/water emulsion for delivery of active ingredient in a medium of cream or lotion for skin cosmetic and/or dermatological care....

20060193812 - Controlled delivery system for fragrance comprising a (meth)acrylate/hydroxy (meth) acrylate copolymer: A perfuming composition for application to the skin by means of a roll-on, pump-spray, squeeze bottle or aerosol spray type device. The composition includes a perfuming base and, optionally, a deodorant or antiperspirant base, with at least one of the bases being combined with a film-forming substrate and an emulsifier...

20060193813 - Nanoemulsion containing a hydroxylated urea compound: The invention relates to an oil-in-water nanoemulsion having an oily phase dispersed in an aqueous phase, the oil globules of which have a number-average size of less than 100 nm, containing: (i) at least one amphiphilic lipid comprising at least one nonionic amphiphilic lipid, and optionally at least one ionic...

20060193815 - Compositions containing amines and use thereof: e

20060193814 - Compositions for the treatment of signs of aging:

20060193816 - Methods and compositions for biocidal treatments: The present invention provides a composition having disinfectancy & residual antimicrobial activity, where the antimicrobial composition comprises an organosilane quaternary compound and a quaternary ammonium compound and other formulations. Also provided are methods of disinfecting an article or providing an antimicrobial coating to an article using the same....

20060193818 - Compositions containing amines and use thereof: e

20060193819 - Topical cosmetic composition with skin rejuvenation benefits: There are provided topical cosmetic compositions for improving the aesthetic appearance of skin and remediating the effects of aging, and methods of use thereof. One composition is a blend of neem seed cell broth and one or more additional botanical ingredients. Another composition has pomegranate fruit extract and, optionally, one...

20060193820 - Immunostimulating polyphosphazene compounds: Polyphosphazene polymers having immunomodulating activity, and the biomedical use of such polyphosphazene polymers, in conjunction with an antigen or an immunogen are disclosed....

20060193822 - Antiseptic spermicidal composition and means for its application: This invention provides a spermicidally and virucidally effective, vaginally applicable formulation, having the following approximate composition of essential ingredients: at least one benzalkonium chloride, in an amount from 0.05 to 0-0.2%; at least one spermicide selected from the group consisting of nonoxynols in an amount of from 0.05-12%, octoxynol-9 in...

20060193821 - Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics: The present invention provides materials and methods to treat immune disease in which cytokines are involved in pathogenesis. The materials and methods of the present invention are useful in the treatment of autoimmune diseases. The materials and methods of the present invention are directed to nucleic acid ligands capable of...

20060193823 - Hydrolytically degradable carbamate derivatives of poly (ethylene glycol): Poly(ethylene glycol) carbamate derivatives useful as water-soluble pro-drugs are disclosed. These degradable poly(ethylene glycol) carbamate derivatives also have potential applications in controlled hydrolytic degradation of hydrogels. In such degradable hydrogels, drugs may be either trapped in the gel and released by diffusion as the gel degrades, or they may be...

20060193824 - Methods for the treatment of infectious and inflammatory airway diseases: Methods for the treatment of inflammatory and infectious airway diseases are disclosed....

20060193826 - Methods to mobilize progenitor/stem cells: wherein each R is independently H or straight, branched or cyclic alkyl (1-6C), n is 1 or 2, and X is an aromatic ring, including heteroaromatic rings, or is a mercaptan; “linker” represents a bond, alkylene (1-6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain,...

20060193827 - Methods using tcf -ii: The present invention provides an agent for preventing and/or treating cachexia comprising TCF-II as an effective ingredient. An agent for preventing and treating cachexia caused by cancer, acquired immunodeficient syndrome (AIDS), cardiac diseases, infectious disease, shock, burn, endotoxinemia, organ inflammation, surgery, diabetes, collagen diseases, radiotherapy, chemotherapy is provided by the...

20060193825 - Pharmaceutical formulations for sustained drug delivery: The present invention provides pharmaceutical formulations comprising a solid ionic complex of a polypeptide having an isoelectric point lower than physiological pH and an anionic carrier molecule. The formulations of the invention are suitable as depot formulations for the sustained release of therapeutic polypeptides....

20060193828 - Expression enhancer for hm1.24 antigen: An enhancer of expression, in the myeloma cell, of HM1.24 antigen, said enhancer comprising interferon-α or interferon-γ, or IRF-2 protein as an active ingredient. Interferon-α or interferon-γ is expected to enhance the expression of HM1.24 antigen by activating the promoter of a gene encoding HM1.24 antigen....

20060193829 - Binding molecules for human factor viii and factor viii-like proteins: It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of...

20060193833 - Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof: The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such...

20060193830 - Raav vector compositions and methods for the treatment of choroidal neovascularization: Disclosed are methods for the use of therapeutic polypeptide-encoding polynucleotides in the creation of transformed host cells and transgenic animals is disclosed. In particular, the use of recombinant adeno-associated viral (rAAV) vector compositions comprising polynucleotide sequences that express one or more mammalian PEDF or anti-angiogenesis polypeptides is described. In particular,...

20060193831 - Use of pleiotrophin to promote neurogeneration: The invention provides methods for promoting neuron survival in patients by administering pleiotrophin, or nucleic acids encoding pleiotrophin. Uses of the invention include promoting neuron graft survival, preventing or reducing nervous system degeneration, and restoring the nervous system, in patients suffering from, or at risk for, neurodegenerative disorders....

20060193832 - Use of the sodium iodine symporter to effect uptake of iodine: The present invention relates to the use of gene therapy to introduce an iodine symporter into cell to increase iodine uptake therein. This approach has particular utility in the treatment of cancers that incapable of removing iodine. In addition, strategies are provided for reducing the export of sodium from cells...

20060193841 - Method for the treatment of parkinson's disease: A method of treating Parkinson's Disease in patients exhibiting increasing resistance to the administration of L-dopa due to loss of aromatic L-amino acid decarboxylic activity in striatal neurons comprises transfection of the caudate and/or putamen regions with a viral vector encoding AADC. The vector preferably has a promoter system provided...

20060193840 - Perivascular mesenchymal precursor cell induced blood vessel formation: Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as STRO-1...

20060193834 - Antiprotozal composition: A composition, and method of use, for controlling, reducing or preventing the growth of protozoal bacteria in the ruman of a rumiant comprising cell bodies of a facultative anaerobe selected from the group consisting of Corynebacterium cell bodies and Brevibacterium cell bodies or a mixture of Corynebacterium cell bodies and...

20060193842 - Formulations to increase in vivo survival of probiotic bacteria and extend their shelf-life: Disclosed is a formulation for preserving the life of probiotic bacteria during passage through the stomach, while permitting their release in the intestine, and which has a low water activity and correspondingly long shelf life. These formulations are designed to retain potency up to the product expiration date. The formulation...

20060193837 - Method and composition for repairing epithelial and other cells and tissue: The present invention is directed to the TVEMF-expansion of mammalian blood stem cells, preferably CD34+/CD38− cells, to compositions resulting from the TVEMF-expanded cells, and to a method of treating a disease or condition or repairing tissue of skin, mouth or ear with the compositions....

20060193836 - Method and composition for repairing heart tissue: The present invention is directed to the TVEMF-expansion of mammalian blood stem cells, preferably CD34+/CD38− cells, to compositions resulting from the TVEMF-expanded cells, and to a method of treating heart disease or repairing heart tissue with the compositions....

20060193838 - Method and composition for treating diabetes: The present invention is directed to the TVEMF-expansion of mammalian blood stem cells, preferably CD34+/CD38− cells, to compositions resulting from the TVEMF-expanded cells, and to a method of treating disease or repairing tissue with the compositions....

20060193839 - Method of providing readily available cellular material derived from peripheral blood, and a composition thereof: The present invention is directed to the TVEMF-expansion of mammalian peripheral blood stem cells, preferably CD34+/CD38− cells, to compositions resulting from the TVEMF-expanded cells, and to a method of treating disease or repairing tissue with the compositions....

20060193835 - Treatment of congestive heart failure: A method of treating congestive heart failure (CHF) in a human patient comprises treating an aliquot of the patient's blood ex vivo with at least one stressor selected from the group consisting of a temperature above or below body temperature, an electromagnetic emission and an oxidative environment, followed by administering...

20060193843 - Thermostable enzyme compositions: The present invention relates to a composition comprising at least two thermostable enzymes selected from the group consisting of endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, and alpha-galactosidase. The thermostable enzymes have a melting temperature, Tm, of at least 70° C. Preferred compositions comprise a xylanase of glycoside hydrolase family...

20060193844 - Methods for enzyme inhibition: Improved regimens for administering proteasome inhibitors are described, wherein proteasome inhibition is more sustained relative to certain current regimens which permit substantial recovery of proteasome activity between doses of inhibitor....

20060193845 - Combination therapy for controlled carbohydrate digestion: Carbohydrate usage in the gastro-intestinal tract of a subject can be modulated by administering, to a subject, a first agent that inhibits carbohydrate degradation in combination with a second agent that decreases formation or severity of intestinal gas....

20060193846 - Carrier with solid fibrinogen and solid thrombin: The present invention relates to a solid composition useful for tissue gluing, tissue sealing and haemostasis consisting essentially of a) a carrier which has at least one of the following physical properties: elasticity module in the range of 5-100 N/cm, density of 1-10 mg/cm3, chamber diameter of more than 0.75...

20060193847 - Peptides for inhibiting retroviruses: Peptides derived from shark immunoglobulin preparations are used to prepare compositions, including pharmaceutical compositions, for inhibiting retrovirus replication in susceptible cells. The peptide preparations are useful for inhibiting diseases associated with retroviral infection, such as acquired immunodeficiency syndrome. The peptides also inhibit growth of tumor cells, especially sarcomas and leukemias....

20060193850 - Anti a beta antibody formulation: The present invention provides formulations for maintaining the stability of Aβ binding polypeptides, for example, Aβ antibodies. Exemplary formulations include a tonicity agent such as mannitol and a buffering agent or amino acid such as histidine. Other exemplary formulations include an antioxidant in a sufficient amount as to inhibit by-product...

20060193849 - Biological materials and uses thereof: A modified antibody molecule which selectively binds to a specific target, the antibody molecule being modified at at least one amino acid residue that determines antigen binding selectivity and/or affinity, characterised in that the modified antibody molecule exhibits a greater stability than an unmodified parent antibody molecule which selectively binds...

20060193851 - Human anti-factor ix/ixa antibodies: The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting...

20060193848 - Mammalian tumor susceptibility genes and their uses: TSG101 is a tumor susceptibility gene whose homozygous functional knock out in fibroblasts leads to transformation and the ability of these cells to form metastatic tumors in nude mice. The cellular transformation that results from inactivation of TSG101 is reversible by restoration of TSG101 function. Decreased expression of TSG101 is...

20060193852 - Novel cd19xcd3 specific polypeptides and uses thereof: Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said...

20060193853 - Combinations of growth-and hormone-regulating factors for the treatment of neoplasia: The invention relates to the field of immunology, endocrinology and oncology and, in particular, the generation of a combined immune response to determined growth factors and hormones. A synergic effect, outlined herein, between growth regulating factors (EGF, TGF and VEGF) and hormones involved in the sexual hormones release cascade or...

20060193854 - Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies....

20060193856 - Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof: The invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives, characterized by a modification at the conserved N-linked site in the CH2 domains of the Fc portion of said antibody. The invention also relates to the treatment of immune response related diseases and inhibition of unwanted immune responses with such...

20060193858 - Cloning and expression of human slap-2: a novel sh2/ sh3 domain-containing human slap homologue having immune cell-specific expression: The present invention describes a newly discovered full-length polynucleotide encoding an SH2/SH3 domain-containing adapter protein, called hSLAP-2, cloned, isolated and identified. Also described are the hSLAP-2 polypeptide sequence, expression vectors, host cells, agonists, antagonists, anti-sense molecules, and antibodies related to the polynucleotide and/or polypeptide of the present invention. Methods for...

20060193855 - Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells: The present invention is directed to novel compositions that cause effective redirection of class I-immunity to Tc1 effectors, that take advantage of the unexpected loading of MHC I by peptide within IgG backbone combined with appropriate instruction of antigen presenting cells. Such compositions are able to transform a seemingly ineffective...

20060193857 - Modulation of fc gamma receptors for optimizing immunotherapy: The present invention relates to methods for modulating the maturation of dendritic cells. In particular, the invention provides methods for (a) promoting the maturation of dendritic cells thereby producing mature dendritic cells, and (b) preventing the maturation of dendritic cells thereby preventing maturation and producing tolerogenic dendritic cells. The present...

20060193859 - Methods of treatment using antibodies to neutrokine-alpha: The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV...

20060193860 - Treatment of schizophrenia: The invention includes methods of treating schizophrenia in a patient where the method includes administration of antibodies to TNF-alpha and interferon-gamma to the patient. The invention further includes methods of treating schizophrenia in a patient where the method comprises administration of an antibody to TNF-alpha....

20060193861 - Tumor necrosis factor receptors 6 alpha & 6 beta: The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6α & -6β proteins. TNFR-6α & -6β polypeptides and antibodies that bind TNFR-6α & -6β polypeptides are also provided as are vectors, host cells and recombinant methods for...

20060193862 - Vascular endothelial cell growth factor antagonists: The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterzied by undesirable or excessive neovascularization....

20060193865 - Camptothecin-binding moiety conjugates: The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates....

20060193863 - Compositions and methods for diagnosing and treating prostate cancer: A method of treating prostate cancer is provided. The method comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of MCP-1 or of an effector thereof, thereby treating the prostate cancer in the subject....

20060193864 - Conversion of apoptotic proteins: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and Bcl-XL are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing apoptosis are described, together with methods for identifying molecules that induce apoptosis through interaction with...

20060193866 - H pylori antigens: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from H. pylori, methods for isolating such antigens and specific uses thereof....

20060193867 - Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith: The present invention relates to molecules that are capable of killing cells. The molecules comprise a targeting agent and a channel-forming moiety. The molecules may be polypeptides. The present invention also relates to polynucleotide sequences encoding the polypeptides of the invention. In a preferred embodiment, the channel-forming moiety comprises a...

20060193868 - Functionalized nanotubes: Graphitic nanotubes, which includes tubular fullerenes (commonly called “buckytubes”) and fibrils, which are functionalized by chemical substitution or by adsorption of functional moieties. More specifically the invention relates to graphitic nanotubes which are uniformly or non-uniformly substituted with chemical moieties or upon which certain cyclic compounds are adsorbed and to...

20060193870 - Compositions and methods for the therapy and diagnosis of colon cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides....

20060193869 - Methods and compositions for induction or promotion of immune tolerance: The invention provides non-immunostimulatory polynucleotide antigen conjugates and methods for treating unwanted immune reactions in individuals using the non-immunostimulatory polynucleotide antigen conjugates....

20060193871 - Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia: Disclosed is a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood flow. A method of treating visceral pain or visceral hypersensitivity in a human subject is also described. A method for prolonging...

20060193872 - Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers: Recombinant VSV viral particles and the use thereof as vaccines for immunization are described....

20060193873 - Functionallly reconstituted viral membranes containing adjuvant: The present invention relates to vaccines directed against antigens such as membrane proteins from pathogens or tumor cells. The invention further relates to methods of forming reconstituted viral membranes, with membrane fusion activity, which are lipid bilayer membranes preferably containing natural lipids of a virus, a viral fusion protein, one...

20060193874 - Vaccines for proliferative ileitis and methods of making and using the same: A proliferative ileitis vaccine comprising tissue culture grown Lawsonia intracellularis and methods of making said vaccines. Proliferative ileitis vaccines described include those containing whole L. intracellularis, extracts of L. intracellularis, protective immunogenic subunits of L. intracellularis, recombinant immunogens of L. intracellularis and naked DNA of L. intracellularis. The vaccines of...

20060193876 - Fusion proteins of mycobacterium tuberculosis: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and...

20060193875 - Method of treating human-immunodeficiency virus (hiv) disease infection: Human Immunodeficiency virus causes depletion of CD4 cells. The depletion of CD4 cells results in decrease in immunity of an infected individual. Due to decrease immunity various opportunistic infections occur. These infections are cause for morbidity and mortality in HIV infected individuals. The treatment of HIV these includes antiretroviral drugs....

20060193877 - Compositions and methods of making sustained release liquid formulations: The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the...

20060193878 - Method of preparing gas delivering perfluorocarbon emulsions with non-fluorinated surfactants: The present invention provides a method of making a FC emulsion. The method comprises mixing an FC immiscible hydrophilic liquid and a solid emulsifying agent by agitation at a temperature elevated above the phase transition temperature of the emulsifying agent and below the boiling temperature of the FC immiscible hydrophilic...

20060193879 - Topical formulations comprising ceramic hydroxyapatite particles: Methods of using absorption enhancer as a component of skin care compositions for moisturizing and protecting the skin. Antimicrobial skin care compositions for cleansing and moisturizing the skin, comprising an absorption enhancer, an antimicrobial function enhancer and bound lipid removals, humectants, emollients and extracts of botanical herbs. Methods for preparing...

20060193880 - Method and compositions for attracting mosquitoes employing (r)-(+)-isomers of 1-alkyn-3-ols: t

20060193881 - Method and compositions for attracting mosquitoes employing (r)-(-) isomers of 1-alken-3-ols:

20060193882 - Particles containing agricultural active ingredients: One or more agricultural active ingredients (such as fungicides or insecticides) are entrapped in polymeric matrixes to form particles having a diameter in the range from about 0.2 to about 200 microns. The particles are applied to soil, to seeds, or to plants and release the active ingredient(s) at a...

20060193883 - Pesticidal treatment materials: The short term effectiveness of pesticidal articles, for example pesticide impregnated textile covers for use in combating dust mite infestation, is improved by the additional presence of a quick release pesticide thereon, e.g. a wettable powder formulation of the same pesticide as used for impregnation. The invention is of particular...

20060193885 - Implantable biomaterial and a method of producing same: The present invention relates to an implantable biomaterial and methods of producing same. In particular, the present invention relates to a method for producing an implantable biomaterial comprising (a) exposing a biomaterial to an alcohol-containing solution for at least 24 hours....

20060193884 - Novel biomaterial drug delivery and surface modification compositions: Compositions are provided which include a polymer made at least in part from a polyoxyalkylene copolymer, such as a poloxamer. The polymer may be combined with a second component to form a blend or emulsion. The resulting composition may be utilized to form medical devices, drug delivery devices, or coatings...

20060193887 - Medical devices having nanoporous bonding layers: The present invention relates generally to medical devices with therapy eluting components and methods for making same. More specifically, the invention relates to implantable medical devices having at least one porous layer, and methods for making such devices, and loading such devices with therapeutic agents. A mixture or alloy is...

20060193886 - Medical devices with nanoporous layers and topcoats: The present invention relates generally to medical devices with therapy eluting components and methods for making same. More specifically, the invention relates to implantable medical devices having at least one porous layer, and methods for making such devices, and loading such devices with therapeutic agents. A mixture or alloy is...

20060193890 - Method for loading nanoporous layers with therapeutic agent: The present invention relates generally to medical devices with therapy eluting components and methods for making same. More specifically, the invention relates to implantable medical devices having at least one porous layer, and methods for making such devices, and loading such devices with therapeutic agents. A mixture or alloy is...

20060193888 - Methods for using medical devices having nanoporous layers: The present invention relates generally to medical devices with therapy eluting components and methods for making same. More specifically, the invention relates to implantable medical devices having at least one porous layer, and methods for making such devices, and loading such devices with therapeutic agents. A mixture or alloy is...

20060193889 - Nanoporous layers using thermal dealloying: The present invention relates generally to medical devices with therapy eluting components and methods for making same. More specifically, the invention relates to implantable medical devices having at least one porous layer, and methods for making such devices, and loading such devices with therapeutic agents. A mixture or alloy is...

20060193893 - Medical devices: The invention relates to medical devices, compositions and methods useful for administrating or delivering a cephalotaxine to a host. The cephalotaxines are useful in treating or preventing an angiogenic condition or disease. The invention provides for medical devices including coatings containing a matrix and a cephtalotaxine to treat an angiogenic...

20060193891 - Medical devices and therapeutic delivery devices composed of bioabsorbable polymers produced at room temperature, method of making the devices, and a system for making the devices: A method is provided of making a bioabsorbable appliance that includes selecting a first bioabsorbable polymer having a first glass transition temperature above about room temperature and selecting a second bioabsorbable polymer having a second glass transition temperature below about room temperature. The method also includes combining the first and...

20060193892 - Polymer biodegradable medical device: A medical device that is at least partially formed of a biodegradable polymer. The medical device can be at least partially formed by MEMS technology. The medical device can include one or more micro-structures that are also formed by MEMS technology. The medical device can include one or more biological...

20060193894 - Methods for providing biomedical devices with hydrophilic antimicrobial coatings: The invention provides a process for producing devices with stable surface coatings, which coatings are one or both of hydrophilic and antimicrobial....

20060193895 - Additive for food and beverage, pharmaceutical composition, glut4 translocator, and method for translocating glut4: e

20060193896 - Process for manufacturing a delivery system for active components as part of an edible composition: A method of manufacturing a delivery system of at least one active component encapsulated in an encapsulating material, which is useful, for example, for providing delayed and/or controlled release of the active is described....

20060193897 - Enzyme feed additive and animal feed including it: The use is provided of a composition as a feed additive which comprises one or more endoglucanases, and 0-20% by weight, based upon the content of cellulase proteins in the composition, of a cellobiohydrolase. The endoglycanases may be one or more of EGI, EGII, EGIII and any functionally active derivative...

20060193898 - Line up of wipes products incorporating targeted sensory elements: Line ups of wipes products are disclosed. In particular baby wet wipe line ups having targeted sensory elements are disclosed. The line ups may have targeted scent elements, targeted visual elements, targeted tactile elements and targeted auditory elements. The sensory elements may be provided in combination to reinforce each other...

20060193899 - Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels: Pharmaceutically acceptable hydrogel polymers of natural, recombinant or synthetic origin, or hybrids thereof, are introduced in a dry, less hydrated, or substantially deswollen state and rehydrate in a physiological environment to undergo a volumetric expansion and to affect sealing, plugging, or augmentation of tissue, defects in tissue, or of organs....

20060193901 - Mixture for transdermal delivery of low and high molecular weight componds: The present invention relates to the discovery of a transdermal delivery system that can deliver high molecular weight pharmaceuticals and cosmetic agents to skin cells. A novel transdermal delivery system with therapeutic and cosmetic application and methods of use of the foregoing is disclosed....

20060193900 - Pressure sensitive adhesive and patch: The present invention is a pressure sensitive adhesive comprising: an ingredient (A) which is a copolymer of a carboxyl group-containing monomer and (meth)acrylic ester; and an ingredient (B) which is a copolymer of a pyrrolidone group-containing monomer and (meth)acrylic ester, wherein the ingredient (A) is crosslinked by at least one...

20060193905 - Direct cellular energy delivery system: A lipid vesicle comprising a phospholipid which is a stable vesicle former and at least one unstable vesicle forming member, wherein the unstable vesicle forming member is selected from the group consisting of a polar lipid which is not a stable vesicle former, a PEG, a raft former and a...

20060193903 - Glycoside-containing liposome: A drug product which can maximize the effect of a cholestanol glycoside useful as an anticancer agent. The present invention provides a liposomal composition containing a glycoside exhibiting antitumor activity, a phospholipid, and a positive-charge-providing substance; the glycoside being composed of GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, or Gal- as a sugar...

20060193904 - Liposome loading with metal ions: This invention relates to encapsulation of drugs and other agents into liposomes....

20060193902 - Pharmaceutical compositions containing active agents having a lactone group and transition metal ions: Compositions and methods for stabilizing an active agent containing one or more actone rings. The compositions, including pharmaceutical compositions, ensure that the lactone ring of the active agent is stabilized in the active, ring-closed form due to the inclusion of a transition metal ion....

20060193906 - Sugar-modified liposome and products comprising the liposome: The present invention provides a sugar-modified liposome having a sugar chain bonded to its membrane surface, preferably through a linker protein, and having excellent absorption qualities, particularly in the intestine. The molecular structure and quantity of the sugar chain is selectively varied to allow the liposome to be delivered in...

20060193907 - Ngna compositions and methods of use: The present invention relates to the field of viral disorders, and in particular to viral obesity. Compositions comprising nutraceutical agents are provided for treating viral obesity. Additionally, compositions comprising nutraceutical agents targeting adenoviruses are provided....

20060193909 - Breath freshening pressed tablets and methods of making and using same: A confectionery product comprises a pressed tablet made from a compressible composition and having at least one abrasive surface suitable for cleaning the surface of a human tongue in an oral cavity. Typically the product has a first side and a second side generally opposite to the first side; the...

20060193908 - Extended release formulations of poorly soluble antibiotics: An extended release pharmaceutical compressed composition and dosage form comprising poorly water soluble macrolide antibiotic, surfactant and non-lipophilic, non-polymeric excipient is disclosed. The composition releases the macrolide antibiotic over an extended period of time, generally at least over 12 hours, even in the absence of a release rate-retarding polymer, release...

20060193910 - Tablets with improved drug substance dispersibility: The present invention relates to a method for the preparation of pharmaceutical compositions in the form of tablets with improved drug substance dispersibility, which method comprises a) preparing a dispersion of at least one pharmaceutically active drug substance and at least one surfactant and/or binder in a liquid; b) preparing...

20060193913 - 5-(4-(2-n-methyl-n-(2-pyridyl)amido)ethoxy)benzyl) thiazolidine-2,4-dione and pharmaceutical compositions comprising the same: A compound, 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (‘Compound (I)’), or a pharmaceutically acceptable form thereof, in particulate form wherein the median value of the volume mean diameter of the particles is within the range 500 nm to 5 micrometres and medicinal uses thereof....

20060193912 - Controlled release o-desmethylvenlafaxine formulations: In certain embodiments, the present invention is directed to a controlled release oral dosage form comprising a therapeutically effective amount of O-desmethylvenlafaxine or a pharmaceutically acceptable salt thereof and a controlled release material; wherein the amount of O-desmethylvenlafaxine or pharmaceutically acceptable salt thereof released at 1 hour in 900 mL...

20060193911 - Controlled release venlafaxine formulations: In certain embodiments, the present invention is directed to a controlled release oral solid dosage form comprising a matrix comprising a therapeutically effective amount of venlafaxine, an active metabolite of venlafaxine, or a pharmaceutically acceptable salt thereof, dispersed in a cross-linked gelling agent, the matrix providing a controlled release of...

20060193914 - Crush resistant delayed-release dosage forms: The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance...

20060193915 - Compression coated tablets: A pharmaceutical composition for oral administration comprising a compression coated solid dosage form of a bitter or unpleasant tasting pharmaceutically active agent. Included are compression coated oral dosage forms of 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide or a pharmaceutically acceptable salt or solvate thereof as active ingredient. The compression coated solid dosage forms are of...

20060193916 - Formulations of peptides for periodontal and dental treatments: Methods to treat the defects in skeletal tissues characterized by protecting the marrow cells adjacent to the defects from apoptotic and/or necrotic cell death are disclosed. The methods provide additional benefits which are to reduce inflammation and irritation in the marrow tissues and assist promoting new skeletal tissue formation to...

20060193917 - Radiosensitizer formulations and methods for use: The present invention provides radiosensitizer compositions, in controlled-release formulations or other acceptable formulations, particularly nitrohistidine radiosensitizer compositions, which may be administered by any suitable means including oral, intravenous, arterial infusion, intraperitoneal, intramuscular, subcutaneous, surgical, and topical. Optionally, radiosensitizer compositions may be formulated with other agents, including chemotherapy agents and agents...

20060193918 - Solvent/polymer solutions as suspension vehicles: A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group...

20060193919 - Complex of drug-carbon nanohorn and a process for producing the complex: The present invention provides a carbon nanohorn complex that is excellent in characteristics of adsorption or inclusion of drugs and release, in particular, a sustained release of drugs as a novel drug carrier in drug delivery systems, as well as a process for producing the complex. The complex of drug...

20060193921 - Hydrophilic beads for use in topical formulations: A composition and method for producing hydrophilic beads for use in topical formulations is described as generally including gellan gum, salts of divalent cations and water. Disclosed features and specifications may be variously controlled, adapted or otherwise optionally modified to realize improved production and/or use of hydrophilic beads to achieve...

20060193920 - Nanoparticulate compositions of mitogen-activated protein (map) kinase inhibitors: Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions....

20060193922 - Compositions and methods for the treatment of acne: This invention relates to compositions for the treatment of acne. In a preferred embodiment, the composition comprises adrenal extract and bupleurum root. In another preferred embodiment, the composition further includes licorice root. In another preferred embodiment, the invention also includes at least one vitamin B5 component, a magnesium component, a...

20060193923 - Compositions and methods for increasing muscle mass and strength, improving athletic performance, and/or reducing body fat mass leading to weight loss: Methods and compositions for the inhibition of human aromatase enzyme are presented for the purposes of increasing or activating the total levels of testosterone, free testosterone, and/or luteinizing hormone levels, while decreasing the levels of estrogen and estradiol. The increase in testosterone levels, combined with a proper exercise and diet...

20060193924 - Antimicrobial combination therapy: This invention provides methods and pharmaceutical compositions for treating a subject having a condition associated with an antibiotic resistant bacterial infection. The invention includes administering to a subject a therapeutically effective combination of an antibiotic and a toxic compound (e.g., a nucleic acid damaging agent, an alkylating agent, or a...

20060193925 - Side effect-relieving agents and/or hypoglycemic effect enhancers for thiazolidine compounds: The present invention relates to a side effect-relieving agent for thiazolidine compounds which comprises a crude drug mixture as an active ingredient comprising Ephedrae Herba, Glycyrrhizae Radix and Gypsum Fibrosum each of which is in a form of ground powders, extracts or mixtures of powders and extracts; and a hypoglycemic...

20060193926 - Di-arylsubstituted pyrrole modulators of metabotropic glutamate receptor-5: Pyrrole compounds of Formula (I): and pharmaceutically acceptable salts thereof (where A, B, R11, R12, R13, W, X, Y and Z are as defined herein), which are substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and...

20060193927 - Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions: This invention relates to combinations of vasoactive substances which are useful in the treatment of sexual dysfunctions associated with poor local blood supply and/or insufficient lubrication. The active compounds are selected from a:—esculoside or visnadine;—forskolin or extracts containing it, or alternatively, purified lipophilic extracts of plants of the genus Ipomea;—esters...

20060193929 - Method for treating or preventing symptoms associated with menopause: The present invention relates to a composition for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs, and a method for treating or preventing a disease, disorder or symptom associated with menopause. The present invention uses a composition comprising as an active ingredient an extract from Cynanchum...

20060193928 - Novel herbal compositions and process for preparation thereof: A process for obtaining various useful extracts from at least one herb includes the steps of extracting lypophilic ingredients through a supercritical CO2 extraction process to obtain a first extract; subjecting the residue thereof to a second supercritical CO2 and alcohol solvent process to obtain slightly polar compounds which define...

20060193930 - Process for the preparation of protein hydrolysate from legumes: The present invention provides a process for the preparation of protein hydrolysate from soy flour, which comprises preparing aqueous slurry of defatted soy flour having 6-12% w/v of solid content, hydrolyzing the said slurry using fungal protease at pH 7-8 and temperature 43±5° C. to get 20-40% degree of hydrolysis...

20060193932 - Morinda citrifolia enhanced colon cancer cell growth inhibitor: The present invention features methods and formulations or compositions for the treatment of colon cancer, and particularly for the inhibition, prevention and/or reduction of cancerous cell growth, as well as the destruction of early stage cancerous cells within the colon region of a mammal, wherein the formulations and compositions comprise...

20060193931 - Nutritional or therapeutic composition containing the compound oleuropeine or one of the derivatives thereof: The present invention provides a nutritional composition and a pharmaceutical composition to be used for humans or animals comprising as active compound the oleuropein compound or one derivative thereof....

20060193933 - Modulation of inflammation by hops fractions and derivatives: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops....

20060188438 - Ethylenedicysteine (ec)-drug conjugates, compositions and methods for tissue specific disease imaging: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a...

20060188437 - Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery: The present invention provides a tumor-homing peptide that can target cancer and or tumor tissues. The peptide is uptaken by certain specific cancer cell types. The invention describes methods to achieve targeted delivery of anticancer drugs conjugated to this peptide for anticancer therapy. The invention also describes methods for using...

20060188440 - Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer: Compositions and methods for detecting and treating cancers expressing Mullerian inhibiting substance Type II receptor (MISIIR) are provided....

20060188439 - Method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection: The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer...

20060188441 - Radiolabeled gallium complexes, methods for synthesis and use for pet imaging of egfr expression in malignant tumors: Methods for labeling synthesis of radiolabeled gallium complex by microwave activation are provided. The resultant gallium-isotope labeled compounds are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). A method for imaging EGFR overexpression in tumors using PET is also provided....

20060188442 - X-ray guided drug delivery: A method of delivering an active agent to a target tissue, particularly neoplastic tissue, vascular anomaly or tumor tissue, in a vertebrate subject. The method includes the steps of exposing the target tissue to ionizing radiation; and administering a delivery vehicle to the vertebrate subject before, after, during, or combinations...

20060188443 - Diagnostic composition for diabetes type-2 and impaired glucose tolerance, and methods of use: A solid oral diagnostic test meal is provided that contains a polysaccharide, wherein the oral diagnostic test meal provides a medically controlled quantity of glycemic carbohydrate after being ingested by a vertebrate subject. In addition, methods and kits are provided for using the diagnostic test meal to monitor postprandial glucose...

20060188444 - Method for monitoring patient or subject compliance with medical prescriptions, and formulation for use in the method: s

20060188445 - Assay for compounds that protect against sensory hair cell death and compounds identified by same: The present invention provides methods of identifying compounds that protect against ototoxicity induced by one or more noxious stimuli, and methods of treating an individual with compounds identified using the present screening methods. Also provided are compounds demonstrated to have otoprotective effects....

20060188446 - T-cell epitope peptides: The T-cell epitope site on a Japanese cypress (hinoki) pollen allergen molecule has been identified by stimulating a T-cell line established from a patient suffering from Japanese cypress pollen allergy with an overlap peptide covering the primary structure of the Japanese cypress pollen allergen. The peptide is useful in peptide-based...

20060188447 - Process for the production of an abuse-proofed dosage form: The present invention relates to a process for the production of an abuse-proofed dosage form containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer (C) with a breaking strength of at least 500 N,...

20060188448 - Theraputic skin treatment method: A method of using a novel candle apparatus at least includes: candle housing; candle fuel deposited in the candle housing, the candle fuel at least including non-toxic solidified therapeutic skin substance; and a candle fuel liquefier; wherein the candle fuel is adapted to, upon application of the fuel liquefier, liquefy...

20060188450 - System and method for suppressing a cough: A system and method for suppressing coughs, congestion and related symptoms is provided. The composition sprayed into the oral cavity may contain a cough suppressant and other ingredients such as decongestants, flavorings, sweeteners, stablizers, and/or preservatives. The composition is sprayed into the oral cavity utilizing a spray pattern having a...

20060188449 - Topical aerosol foams: A stable topical aerosol foam is provided. The foam-forming formulation includes a HFA propellant and an active agent in an emulsion. The emulsion has an oil phase and an aqueous, i.e. water-containing, phase. The active agent may be present in either phase or dispersed in the emulsion. The oil phase...

20060188451 - Aerogel based pharmaceutical formulations: Drugs in the form of very fine highly porous aerogel particles are delivered to a patient via inhalation. The aerogel particles are either an aerogelized form of a pharmaceutical or deposited upon aerogel particles produced from a non-inorganic oxide carrier matrix material, e.g. a sugar or carbohydrate. The aerogel particles...

20060188454 - Oral compositions and use thereof: The invention comprises the use of oral compositions of defined rheological characteristics in oral treatment systems, especially a hand-held electric toothbrush, comprising a reservoir and means for pumping the oral composition from the reservoir to an applicator such as a toothbrush head. Pumpable oral compositions having good stand-up on a...

20060188452 - Treatment composition: The invention relates to a dental treatment composition comprising a particulate erasing agent, the particles of the erasing agent being dimensioned to roll along a surface. The particles have an average maximum diameter of between 30 and 1000 microns and consist of a precipitate of calcium carbonate. As the particles...

20060188453 - Use of substitute 2,4-bis (alkylamino)pyrimidines: The use of 2,4—bis(alkylamino)pyrimidines of formula (1) R1 is C1-C12alkyl or C6-C10laryl; R2 is hydrogen or C1-C12alkyl; or R1 and R2 together form a radical of formula (1a) R′ and R″ are each independently of the other hydrogen, C1-C6alkyl or C1-C6alkoxy, R3 and R5 are each independently of the other...

20060188457 - Bodywashes containing additives: The invention encompasses bodywashes containing an additive. The additive may contain a sunscreen. The additive may contain 2, 3, or more than three sunscreens. Optionally, one or more of the sunscreens may be encapsulated. The invention further encompasses methods of making and using bodywashes containing an additive, e.g., an additive...

20060188455 - Siloxanes containing guanidino groups and use thereof for cosmetic formulations: The invention relates to polysiloxanes containing guanidino groups for which the guanidino groups can be combined arbitrarily with other functional groups on the polysiloxane backbone according to the general formula (I)...

20060188458 - Sunscreen compositions and methods of use: The invention encompasses additives for addition to a bodywash, where the additives contain one or more sunscreens, and where a bodywash which contains the additive imparts to the skin an SPF of at least about 2, in some cases at least about 5, or 10, or 15. Also described are...

20060188456 - Uv-light-absorbing quaternary polysiloxanes: The invention relates to UV-light-absorbing quaternary polysiloxanes in which quaternary groups and UV-absorbing radicals can be mixed independently of one another according to the general formula (I)...

20060188459 - Cosmetic, pharmaceutical or dermatological preparations comprising copolymer waxes: Cosmetic, pharmaceutical and dermatological preparations are described which contain copolymer waxes. The copolymer waxes contain structural units which are derived from α-olefins having 26 to 60 carbon atoms, from maleic anhydride, maleic acid or salts thereof and optionally from further monomers....

20060188460 - Solid hair conditioning product: A cosmetic product (1) for conditioning hair, the cosmetic product having the form of a solid and comprising at least one hair conditioning ingredient. Cocoa butter, cetearyl alcohol (and) sodium lauryl sulfate and glyceryl stearate (and) PEG 100 stearate are used to form the solid and the at least one...

20060188461 - Linear sulfonic polyester as a water-resistant hair fixing agent: The present patent application relates to the use of at least one water-dispersible linear sulfonic polyester as a hair fixing agent that is resistant to liquid water....

20060188462 - Skin care compositions containing a sugar amine: Topical skin care compositions containing sugar amines in combination with selected skin care actives and methods of using such compositions to regulate the condition of skin are disclosed. The compositions contain a safe and effective amount of a sugar amine in combination with either a safe and effective amount of...

20060188466 - Cosmetic composition comprising at least one fixing polymer and at least one amphoteric starch: A cosmetic composition for the treatment of keratinous fibres, in particular hair, comprising at least one fixing polymer and at least one amphoteric starch and the process for treatment of keratinous fibres using said composition....

20060188465 - Cross-linked polymer of carbohydrate, notably based on polysaccharides, and/or on oligosaccharides and/or on polyols: The invention discloses a cross-linked polymer of at least one carbohydrate component comprising at least one primary alcohol function in particular for the manufacture of a composition which is intended to be applied onto the skin to obtain a tensing and/or toning effect....

20060188464 - Microencapsulation systems and applications of same: The invention relates to microencapsulation systems which are characterised in that they are developed from oily substances or sugars and in that they form an essentially organised assembly corresponding to stacks of crystalline structures. The inventive systems can be used for the microencapsulation of one or more substances which are...

20060188467 - Skin care composition containing a sugar amine: Topical skin care compositions containing sugar amines in combination with selected skin care actives and methods of using such compositions to regulate the condition of skin are disclosed. The compositions contain a safe and effective amount of a sugar amine in combination with either a safe and effective amount of...

20060188463 - Stable water-in-oil-in-water multiple emulsion system produced by hydrodynamic dual stabilization and a method for preparation thereof: The present invention relates to a water-in-oil-in-water multiple emulsion system and a method for preparation thereof, characterized by hydrodynamically stabilizing the multiple emulsion system by using hydrodynamic dual stabilization (HDS) technology. The HDS technology hydrophobizes water molecules in the internal aqueous phase by using a hydrogen bonding inhibitor and by...

20060188468 - Cosmetic and pharmaceutical substances based on polyelectrolyte complexes: The present invention relates to cosmetic and pharmaceutical compositions which comprise at least one polyelectrolyte complex which comprises a copolymer with cationogenic groups based on vinylimidazole and an acid-group-containing polymer. The invention further relates to the use of these polyelectrolyte complexes....

20060188469 - Vaccine delivery compositions and methods of use: The present invention provides synthetic vaccine delivery compositions based on polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) polymers for stimulating an immune response to a variety of pathogenic organisms and tumor cells in humans and other mammals. The vaccine delivery compositions are formulated as a liquid dispersion...

20060188470 - Pes 2000 plus folic acid: 1. A therapeutic dose of PES 2000 when taken orally by animals or humans helps to control and prevent epilepsy....

20060188473 - Compositions and methods for repressing b cell autoantibody secretion and for treating autoimmune disorders: The invention provides isolated regulatory immune cells as well as cell cultures and conditioned media derived therefrom. Also provided are methods of repressing B cell autoantibody production and/or secretion and methods of treating autoimmune disorders using regulatory immune cells or precursors thereto. Further provided are methods of diagnosing in a...

20060188472 - Has-active ingredient conjugates: The invention relates to compounds comprising a conjugate of hydroxyalkyl starch (HAS) and an active agent, whereby the hydroxyalkyl starch is either directly covalently bonded to the active agent, or by means of a linker. The invention further relates to methods for the production of a covalent HAS-active agent conjugate,...

20060188471 - Methods of treating epithelial lesions: The invention features methods of preventing or treating epithelial cell lesions in a mammal by administering a composition containing a therapeutically effective amount of a trefoil domain-containing polypeptide, or a trefoil peptide fragment, and a mucoadhesive excipient. The invention further features methods of preventing or treating an eye disorder, e.g.,...

20060188474 - Interleukin 1beta protease and interleukin 1beta protease inhibitors: wherein R1 and R3 are independently any D or L isomer amino acid, R2 is Ala or Gly, and wherein the specific protease cleavage site is between Asp and R2. Inhibitor compounds, compositions and methods for inhibiting Interleukin 1β protease activity are also disclosed. The inhibitor compounds comprise an amino...

20060188476 - Interleukin 20 (il-20) and its use in neovascularisation: The invention provides a novel method of regulating neovascularisation....

20060188475 - Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders: Methods of treating, preventing and/or managing an immunodeficiency disease or disorder are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active agent. Methods of boosting humoral immunity are also disclosed....

20060188478 - Glycosylated interferon: This invention provides for human interferon-α which includes novel glycosylation structures....

20060188477 - Use of interferon alpha 5 in the treatment of viral liver diseases: The invention relates to the use of interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFNα5 in the livers of patients with hepatitis C in comparison to healthy livers. The sub-type of IFN expressed in said healthy livers corresponded only to the...

20060188479 - Adenovirus vectors containing cell status-specific response elements and methods of use thereof: The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using...

20060188482 -